Literature DB >> 20123067

HMGA and cancer.

Monica Fedele1, Alfredo Fusco.   

Abstract

Long-standing studies have clearly established that the architectural chromatinic proteins High Mobility Group A (HMGA) are among the most widely expressed cancer-associated proteins. Indeed, their overexpression represents a constant feature of human malignancies, and correlates with a poor prognosis. Moreover, HMGA dysregulation, as a result of specific chromosomal rearrangements, occurs in a broad variety of common benign mesenchymal tumors, making HMGA genes among the most commonly rearranged genes in human neoplasms. Nevertheless, recent data propose a critical role of HMGA overexpression also in the generation of pituitary adenomas. Here, we review the involvement of HMGA proteins in cancer, analyzing the mechanisms underlying their crucial role in tumorigenesis, and, finally, discuss the potentiality of a cancer treatment based on HMGA targeting. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20123067     DOI: 10.1016/j.bbagrm.2009.11.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  77 in total

1.  Elevated HMGN4 expression potentiates thyroid tumorigenesis.

Authors:  Jamie Kugler; Yuri V Postnikov; Takashi Furusawa; Shioko Kimura; Michael Bustin
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

2.  Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer.

Authors:  Gabriele Sulli; Raffaella Di Micco; Fabrizio d'Adda di Fagagna
Journal:  Nat Rev Cancer       Date:  2012-09-06       Impact factor: 60.716

3.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

4.  History of uterine leiomyoma and risk of endometrial cancer in black women.

Authors:  Lauren A Wise; Todd R Sponholtz; Lynn Rosenberg; Lucile L Adams-Campbell; Wendy Kuohung; Michael P LaValley; Julie R Palmer
Journal:  Cancer Causes Control       Date:  2016-02-29       Impact factor: 2.506

5.  HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.

Authors:  Bo Pang; Haitao Fan; Ian Y Zhang; Bin Liu; Bin Feng; Lei Meng; Rui Zhang; Sam Sadeghi; Hua Guo; Qi Pang
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

6.  HMGA1 negatively regulates NUMB expression at transcriptional and post transcriptional level in glioblastoma stem cells.

Authors:  Francesca Puca; Nadia Tosti; Antonella Federico; Yalçın Kuzay; Anna Pepe; Sonia Morlando; Teresa Savarese; Federica D'Alessio; Marianna Colamaio; Daniela Sarnataro; Sihana Ziberi; Marco De Martino; Alfredo Fusco; Sabrina Battista
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

7.  CBX7 is a tumor suppressor in mice and humans.

Authors:  Floriana Forzati; Antonella Federico; Pierlorenzo Pallante; Adele Abbate; Francesco Esposito; Umberto Malapelle; Romina Sepe; Giuseppe Palma; Giancarlo Troncone; Marzia Scarfò; Claudio Arra; Monica Fedele; Alfredo Fusco
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

8.  The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.

Authors:  Paula Mussnich; Daniela D'Angelo; Vincenza Leone; Carlo Maria Croce; Alfredo Fusco
Journal:  Mol Oncol       Date:  2013-01-17       Impact factor: 6.603

9.  Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.

Authors:  Zhizhong Li; Yunyu Zhang; Krishnan Ramanujan; Yan Ma; David G Kirsch; David J Glass
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

10.  HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells.

Authors:  Suchitra Natarajan; Sabine Hombach-Klonisch; Peter Dröge; Thomas Klonisch
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.